RCRongyu Chen

Rongyu Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rongyu Chen has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Jin Wang

    Department of Medical Genetics and Prenatal Diagnosis, Sichuan Provincial Woman's and Children's Hospital, No. 290 West Second Street, Shayan Road, Chengdu, 610045, China.

    2 shared publications
  • Shaoke Chen

    Department of Genetic Metabolism, Children's Hospital, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning 530003, People's Republic of China; GuangXi Center for Birth Defects Research and Prevention, Nanning 530003, People's Republic of China

    2 shared publications
  • Yiping Shen

    Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China

    2 shared publications
  • Bing Guo

    State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, China

    1 shared publication
  • Bobo Xie

    Genetic and Metabolic Central Laboratory, Guangxi Maternal and Child Health Hospital, Nanning, Guangxi, PR China

    1 shared publication
  • Bobo Xie

    Department of Genetic and Metabolic Central Laboratory, Guangxi Maternal and Child Health Hospital, No.59, Xiangzhu Road, Nanning, China

    1 shared publication

Latest Publications

  • Open Access

    miR ‐124‐3p improves mitochondrial function of renal tubular epithelial cells in db/db mice

    by Luqun Liang, Chunxin Wo, Yao Yuan, Hongjuan Cao, Wanlin Tan, Xingcheng Zhou, Dan Wang, Rongyu Chen, Mingjun Shi, Fan Zhang, et al.

    Diabetic kidney disease (DKD) is one of the most serious complications of diabetes mellitus (DM) and the main cause of end‐stage renal failure. However, the pathogenesis of DKD is complicated. In this study, we found that miR‐124‐3p plays a key role in regulating renal mitochondrial function and explored its possible mechanism in DKD progression by performing a series of in vitro and in vivo experiments . Decreased expression of miR‐124‐3p was found in db/db mice compared to db/m mice. Moreover, miR‐124‐3p down‐regulated FOXQ1 by targeting FOXQ1 mRNA 3′‐UTR in NRK‐52E cells. Also, an increase in FOXQ1 and down‐regulation of Sirt4 were found in db/db mouse kidney and renal tubular epithelial cells cultured with high glucose and high lipid. Overexpression of FOXQ1 could further down‐regulate the expression of Sirt4 and aggravate the damage of mitochondria. Conversely, the knockdown of the FOXQ1 gene induced Sirt4 expression and partially restored mitochondrial function. To verify the effects of miR‐124‐3p on Sirt4 and mitochondria, we found that miR‐124‐3p mimics could up‐regulate Sirt4 and inhibit ROS production and MitoSOX, thus restoring the number and morphology of mitochondria. These results showed that under high‐glucose and high‐lipid conditions, the down‐regulation of miR‐124‐3p induces FOXQ1 in renal tubular epithelial cells, which in turn suppresses Sirt4 and leads to mitochondrial dysfunction, promoting the development of DKD.


  • Thyroglobulin gene mutations in Chinese patients with congenital hypothyroidism

    by Xuyun Hu, Rongyu Chen, Chunyun Fu, Xin Fan, Jin Wang, Jiale Qian, Shang Yi, Chuan Li, Jingsi Luo, Jiasun Su, et al.


  • Open Access

    EPHA4 haploinsufficiency is responsible for the short stature of a patient with 2q35-q36.2 deletion and Waardenburg syndrome

    by Chuan Li, Rongyu Chen, Xin Fan, Jingsi Luo, Jiale Qian, Jin Wang, Bobo Xie, Yiping Shen, Shaoke Chen

    Waardenburg syndrome type I (WS1), an auditory-pigmentary genetic disorder, is caused by heterozygous loss-of-function mutations in PAX3. Abnormal physical signs such as dystopia canthorum, patchy hypopigmentation and sensorineural hearing loss are common, but short stature is not associated with WS1. We reported a 4-year and 6 month-old boy with a rare combination of WS1 and severe short stature (83.5 cm (−5.8SD)). His facial features include dystopia canthorum, mild synophrys, slightly up-slanted palpebral fissure, posteriorly rotated ears, alae nasi hypoplasia and micrognathia. No heterochromia was noticed. He had a normal intelligence quotient and hearing. Insulin-like growth factor-1 (IGF-1) was 52.7 ng/ml, lower than the normal range (55 ~ 452 ng/ml) and the peak growth hormone level was 7.57 ng/ml at 90 minutes after taking moderate levodopa and pyridostigmine bromide. The patient exhibited a good response to human growth hormone (rhGH) replacement therapy, showing a 9.2 cm/year growth rate and an improvement of 1 standard deviation (SD) of height after one year treatment. CMA test of patient’s DNA revealed a 4.46 Mb de novo deletion at 2q35-q36.2 (hg19; chr2:221,234,146-225,697,363). PAX3 haploinsufficiency is known to cause Waardenburg syndrome. Examining overlapping deletions in patients led to the conclusion that EPHA4 is a novel short stature gene. The finding is supported by the splotch-retarded and epha4 knockout mouse models which both showed growth retardation. We believe this rare condition is caused by the haploinsufficiency of both PAX3 and EPH4 genes. We further reported a growth response to recombinant human growth hormone treatment in this patient.